Reuters logo
8 个月内
BRIEF-Epizyme announces fast track designation for Tazemetostat in DLBCL
2016年11月28日 / 中午11点57分 / 8 个月内

BRIEF-Epizyme announces fast track designation for Tazemetostat in DLBCL

1 分钟阅读

Nov 28 (Reuters) - Epizyme Inc :

* Epizyme announces fast track designation for tazemetostat in DLBCL and provides solid tumor program update

* Epizyme announces fast track designation for tazemetostat in dlbcl and provides solid tumor program update

* Epizyme inc - Epizyme plans to present data from phase 2 trial in first half of 2017

* Fda granted Tazemetostat fast track designation in patients with diffuse large b-cell lymphoma with EZH2 activating mutations Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below